Repeated low-dose (RLD) challenge designs are important in HIV vaccine research. Current methods for RLD designs rely heavily on an assumption of homogeneous risk of infection among animals, which, upon violation, can lead to invalid inferences and underpowered study designs. We propose to fit a discrete-time survival model with random effects that allows for heterogeneity in the risk of infection among animals and allows for predetermined challenge dose changes over time. Based on this model, we derive likelihood ratio tests and estimators for vaccine efficacy. A two-stage approach is proposed for optimizing the RLD design under cost constraints. Simulation studies demonstrate good finite sample properties of the proposed method and its superior performance compared to existing methods. We illustrate the application of the heterogeneous infection risk model on data from a real simian immunodeficiency virus vaccine study using Rhesus Macaques. The results of our study provide useful guidance for future RLD experimental design.
INTRODUCTION
Recently, a repeated low-dose (RLD) challenge design has become a standard approach to using nonhuman primate (NHP) models in HIV vaccine research. Instead of exposing animals to a single high dose of virus to induce infection as in traditional challenge experiments, in RLD experiments animals are repeatedly challenged with a relatively low dose of virus. For example, Qureshi and others (2012) adapted RLD experiments to determine whether the combination of host range mutant adenovirus type-5 and simian immunodeficiency virus (SIV; Ad5 SIVmac239 Gag/Pol/Nef) vaccine has a significant effect on SIV
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297 intensive simulation studies in Section 4. In Section 5, an application of the proposed risk modeling method to the NHP study described in Qureshi and others (2012) is presented. Finally, we conclude the article with a discussion of our findings and future research topics.
A HETEROGENEOUS INFECTION RISK MODEL

Notation and assumptions
Here we consider an RLD experiment in which each animal is randomly assigned to a treatment (vaccine) or a placebo group, and all animals are repeatedly challenged with the same series of SIVs. Let i be the subject index, Y i and C i be time to infection and time to censoring, respectively, and T i = Y i ∧ C i be the time to event outcome variable whichever comes first between Y i and C i . An infection indicator is denoted by δ i = 1{Y i C i }, where 1{A} = 1 if A is satisfied, 0 otherwise. Suppose the animals' infection statuses are collected after each challenge. T i is thus discrete and can be represented as the total number of challenges an animal receives until infected or censored. Let X i be a p × 1 vector of time-invariant baseline covariates such as the indicator of vaccination status. Let Z i (t) be a vector of time-variant covariates associated with the challenge dose that animal i receives at time t. For example, when d different levels of challenge doses are applied to each animal, in this article we model Z i (t) = {Z i1 (t), Z i2 (t), . . . , Z id (t)}, where Z i1 (t) = 1 for all dose levels (reference level), Z ik (t) = 1 for the kth dose level, and Z ik (t) = 0 otherwise for k = 2, . . . , d. Alternatively, Z i (t) can include polynomial terms of challenge doses at time t if one is interested in continuous dose effects. Let Z H i (t) = {Z i (u) : 1 u t} denote the history of Z i up to time t. We observe n independent identically distributed (i.i.d.) samples,
We consider a study design where dose levels are predetermined by protocol for the whole study period and do not vary with individual subjects. That is, Z i (t) = Z (t) is determined in advance for all individuals under study for t within the planned study period and is conceptually an external time-dependent covariate as described in Kalbfleisch and Prentice (2011) .
Let R i denote the subject-specific random effect. We make the following three assumptions. First, the infection risks across challenges within an animal are assumed to be independent of each other conditional on the random effect and covariates included in the risk model. Second, non-informative censoring is assumed, conditional on the random effect and covariates, which is a reasonable assumption for a well-controlled RLD experiment. Finally, we assume that there is no "memory" of challenge history as commonly assumed in RLD literature (García-Lerma and others, 2008; Hudgens and others, 2009; Regoes, 2012) . That is, for an animal not yet infected before a challenge, the probability of infection at this particular challenge depends only on the current challenge but not on previous challenges.
A discrete-time survival model with random effects and a marginal likelihood approach
Let β and α represent vectors of regression parameters for X and Z , for example, the effects of vaccination and challenge doses (α = (α 1 , . . . , α d ) T ), respectively. To take into account between-animal heterogeneity under the aforementioned assumptions, we model the risk of infection as follows:
where the random effect R i follows a specific distribution and g is a link function. Model (2.1) could be extended to include interactions between dose-levels and treatment:
. . , Z id (t)}, and γ quantifies how the treatment effect changes with dose level. In this study, we use a clog-log link for g and assume that W i = exp(R i ) is 298 C. KANG AND OTHERS independent of other covariates and follows a γ-distribution with mean 1 and variance ν. A γ-distribution with various shapes covers many commonly used exponential-family distributions. Modeling the risk of infection (2.1) with a γ-distributed random effect and a clog-log link function leads to a closed-form expression for the marginal likelihood and the vaccine efficacy, which is computationally efficient. We refer to Conaway (1990) , Scheike and Jensen (1997) , and Coull and others (2006) for further discussion on the advantages of this combination of the random effects model and link function. In a discrete-time survival model, given that Z i is an external covariate, the conditional survival function at time t is S i (t|Z
, and the conditional probability of infection at time t is f i (t|Z
where G is the cumulative distribution function (CDF) of R. Let η i ( j) = Z i ( j)α + X i β denote the linear predictor at the time of challenge j. As shown in supplementary material available at Biostatistics online, Section S1,
Therefore, we have a closed-form formula for the marginal log-likelihood function:
where P n is the standard empirical measure for
Estimation and inference
We estimate parameters in (2.1) and variance ν by maximizing the log likelihood (2.2), for example, through Fisher scoring using iteratively reweighted least squares. The variability of the random effects can be expressed more intuitively by an intracluster correlation, ρ, between underlying continuous responses. In particular, let B i (t) be a binary outcome indicating infection status for animal i after the tth challenge assuming no event occurs before t. Let C i (t) be the underlying continuous latent outcome such that
, where − i (t), the individual error term, has a reverse extreme value distribution with the CDF H {ε i (t)} = exp[− exp{−ε i (t)}] and variance π 2 /6. Under the model with a γ-distributed random effect and a clog-log link, the intrasubject correlation coefficient for the underlying continuous outcome equals ρ = ν/(ν + π 2 /6). Equivalently, we have ν = π 2 ρ/{6(1 − ρ)}. For more details, we refer to Coull and others (2006) and Rodrıguez and Elo (2003) .
The null hypothesis of no between-animal heterogeneity, ν = 0, is equivalent to the null hypothesis of no random effects, R = 0, for all animals. Under the null hypothesis,
which is a likelihood function assuming independent risk of infection across challenges. As shown in supplementary material available at Biostatistics online, Section S1, (2.2) converges to (2.3) as ν → 0.
, β ∈ R, ν = 0} denote parameter spaces under the alternative and null hypotheses of zero between-animal heterogeneity, respectively. We conduct the likelihood ratio test (LRT) to reject the null hypothesis for a large value of the LR statistic:
Under the null hypothesis of ν = 0, the value of ν lies on the boundary of the parameter space, ν ∈ [0, ∞), such that ν converges to a mixture of χ 2 distributions 0.5χ , as presented in Self and Liang (1987) , Goldman and Whelan (2000) , and . We reject H 0 :
The test for the effect of vaccine is equivalent to the test of the null hypothesis H 0 :
} denote parameter spaces under the alternative and null hypotheses of a zero vaccine effect, respectively. We reject the null hypothesis if −2 lnˆ β > χ
β }, and r is the difference in the number of parameters between the two-nested models.
Estimation of vaccine efficacy
Hudgens and Gilbert (2009) defined two types of vaccine efficacy. The first is vaccine efficacy for preventing infection before or at the time of challenge t: VE(t) = 1 − probability of infection before or at time t for the vaccine group probability of infection before or at time t for the placebo group , which is the relative reduction in the risk of infection before or at time t for the vaccine group compared to the placebo group. VE(t) > 0 indicates that the vaccine is effective in reducing the risk of infection before or at time t, whereas VE(t) 0 indicates that the vaccine is not effective or has a negative effect. Under the heterogeneous infection risk model described in Section 2.2,
. The second type of vaccine efficacy is the perchallenge vaccine efficacy, defined as the relative reduction in the risk of infection caused by vaccination at a particular challenge, conditional on non-infection before the challenge. Perchallenge VE at dose-level k under the heterogeneous infection risk model equals
where Z k is a vector of variables of length d for the kth dose level with the th element being 1{ = k}, = 2, . . . , d and Z 1 = 1 (reference level). VE k allows characterization of the vaccine's effect at a specific level of exposure, whereas VE(t) represents a vaccine effect integrated over multiple levels of exposures. LetVE(t) andVE k be MLE of VE(t) and VE k . The covariance matrices ofVE(t) andVE k can be calculated using the Delta method as given in supplementary material available at Biostatistics online, Section S1.
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OPTIMIZATION OF THE DESIGN OF RLD EXPERIMENTS UNDER COST CONSTRAINTS
In practice, we have limited resources for conducting RLD experiments. It is of interest to optimize the study design such that a desired operational criterion, for example, precision of VE estimators or power of the study, can be maximized. As pointed out by Moerbeek (2012) and Zhang and Ahn (2011) for the cluster randomized design with discrete survival outcomes, no analytical formula is available yet for calculating sample size and power; Monte-Carlo simulation studies are commonly used to determine design components. The results of the simulation study in demonstrated that the statistical power for the test of vaccine efficacy increases with larger sample size, larger maximum number of challenges per animal, and higher risk of infection per exposure in the control group. Optimizing an RLD design typically requires excessive simulations under various combinations of sample size and number of challenges.
Motivated by the study in Zhang and Ahn (2011), we propose a computationally efficient two-stage approach to identify the optimal pair of sample size and maximum number of challenges, denoted by (n * , m * ), in order to maximize the operational criteria of interest under financial constraints. We illustrate how the proposed approach can be used to guide the design of an RLD experiment to optimize the efficiency of estimating perchallenge vaccine efficacy, VE k . The same strategy applies to other criteria such as VE(t) and study power.
Suppose the financial costs of adding an animal and adding a challenge per animal are C 1 and C 2 , respectively, and the maximum budget C for the experiment is fixed. Suppose d unique levels of escalating challenge doses will be applied to each animal as in Qureshi and others (2012) , and each dose level is applied to an animal for m times (m 2). Let q j denote the probability of an animal receiving the jth challenge for j = 1, . . . , d × m. The average cost to challenge n animals for up to m times at each dose level equals nC 1 + n d×m j=1 q j C 2 C. Define n(m) as the largest n for a given m satisfying this constraint:
, where x denotes the largest integer not greater than x. Since n and m are not independent conditional on C, seeking the best pair (n * , m * ) that minimizes the variance for estimators of VE k is not straightforward in practice, particularly for a complex study design like an RLD experiment.
Let
We propose to use a twostage approach to find (n * , m * ). In the first stage, we conduct a simulation study with a large sample size (N ) to estimate Var(VE k ) for each m ∈ M, denoted byV ar(VE k ) {N ,m} . In the second stage, we find the {n(m), m} ∈ S (n,m) that minimizes the variance estimate ofV E k . In particular, letV ar(VE k ) {n(m),m} denote the variance estimate based on data with {n(m), m}. We approximateV ar(VE k ) {n(m),m} witĥ Var(VE k ) {N ,m} × N /n(m) . Using m = 2 as the reference design, we evaluate the efficiency at {n(m), m} relative to {n(2), 2} by
The resultant (n * , m * ) would achieve the best efficiency for estimating VE k under a fixed total cost. Compared with the typical Monte-Carlo simulation studies that evaluate variances ofVE k estimators for every n, m combinations, the computational burden reduces from O(n) × O(m) to O(m) using the proposed two-stage approach.
SIMULATION STUDIES
We illustrate the proposed heterogeneous infection risk model and the two-stage approach to optimizing RLD design with two intensive simulation studies. In the first simulation study, we compare the discretetime survival model with random effects (hereafter "heterogeneous model") with a discrete-time survival model assuming independence in the risk of infection across challenges within animals ("homogeneous model"), with respect to statistical power, Type I error rate and the precision of parameter estimates. In the second simulation study, we explore the best pair of sample size and maximum number of challenges per animal for various levels of vaccine efficacy and between-animal heterogeneity under a fixed total cost.
For both simulation studies, we considered RLD studies in which animals are 1 : 1 randomized to a vaccine group and a placebo group and challenged with the same three increasing levels of challenge doses (d = 3) to mimic the setting in Qureshi and others (2012) . Each animal was allowed up to d × m challenges. Let X i be the indicator of assignment to the vaccine group and Z i ( j) = {Z i1 ( j), Z i2 ( j), Z i3 ( j)} as defined in Section 2.1. Let R i = log(U i ) be a random effect with U i generated from a γ-distribution with mean 1 and variance ν. The conditional probability of infection at each challenge was modeled as in (2.1) with the clog-log link function. We observed the binary outcome T corresponding to perchallenge infection probabilities among placebo recipients of 0.02, 0.16, and 0.39 at dose levels 1, 2, and 3, respectively. Sample sizes n = 40, 200, or 1000 were explored. For each simulation scenario, 1000 Monte-Carlo data were generated.
4.1.2
Results. Without within-animal dependence (ν = 0), average estimates for model parameters and for perchallenge VEs using the heterogeneous model were comparable with those estimated using the homogeneous model, with slightly larger variances. In the presence of weak within-animal dependence (ν = 0.89), the homogeneous model produced highly biased estimates while the heterogeneous model produced unbiased estimates even when sample size was small (Table 1 ). In addition, perchallenge VE tended to be underestimated by fitting the homogeneous model with much worse coverage rates, while the heterogeneous model produced unbiased estimates with coverage rates close to the target nominal level (Table 2) . Results for the settings with moderate or strong within-animal dependence, presented in supplementary material available at Biostatistics online, Tables S1 and S2, showed the apparent superiority of the heterogeneous model. Supplementary material available at Biostatistics online, Figure S1 , shows the estimate of VE(t) versus t. The homogeneous model underestimated VE(t), particularly at the early stages of the study, while the estimated VE(t) curve using the heterogeneous model was very close to the true VE(t) curve.
For settings with ν > 0, LRT testing for vaccine effects using the homogenous model had elevated Type I error rates, while LRT using the heterogeneous model and the log-rank test by contrast had Type I error rates close to the target nominal level (Table 3) . LRT using the heterogeneous model produced the highest power; the gain in power by accounting for within-animal dependence increased as ν increased. In general, power for testing vaccine effects decreases as ν increases. Consequently, a much larger sample size will be required to detect a weak vaccine effect in the presence of moderate or strong within-animal dependence. Supplementary material available at Biostatistics online, error rates, and the power of the test increased with the sample size and the magnitude of the within-animal dependence.
More results of the simulation study investigating the performance of the heterogeneous model are presented in supplementary material available at Biostatistics online, Tables S4-S9 in Sections S2 and S3. A similar pattern comparing heterogeneous and homogenous models was observed in the extended model that includes interactions between the dose levels and vaccine assignment (supplementary material available at Biostatistics online, Tables S7-S9). We also investigated the robustness of the proposed model under risk model misspecification. Results are presented in supplementary material available at Biostatistics online, Tables S10-S11 in Section S4. In general, the proposed heterogeneous model has a compatible or slightly better performance compared with the homogeneous model or the log-rank test under a moderate degree of working model misspecification. T were chosen such that the perchallenge probabilities of infection in the placebo group for ν = 0.89, 2.01, and 4.93, equal 0.1, 0.09, and 0.08, respectively, at dose level 1, 0.18, 0.17, and 0.14 at dose level 2, and 0.27, 0.24, and 0.19 at dose level 3. Various values for β corresponding to VE 1 = 0.2, 0.5, or 0.7 were considered, where VE 1 is perchallenge vaccine efficacy at the lowest level dose. We assumed that the cost for adding an animal is 50 times the cost for an extra challenge per animal and set the maximum budget to be C = 300 × C 1 . A range of the maximum number of challenges per dose level, M = {m : m = 2, 3, . . . , 15}, were considered to allow for at least two challenges at each dose level.
Results.
Our goal was to identify the optimal pair of sample size and maximum number of challenges per animal to achieve the best efficiency in estimating VE 1 given budget constraints. In the first stage, we estimated the variance ofVE 1 for each {n(m), m} ∈ S (n,m) using 10 simulated datasets, each containing N = 5000 samples. In the second stage, we calculated RE{n(m), m}, the efficiency ofVE 1 for {n(m), m} relative to {n(2), 2} by (3.1) and averaged RE{n(m), m} over the 10 simulated datasets to obtain a smooth estimate. We then identified the best pair of {n(m), m} that achieved the greatest average relative efficiency compared with {n(2), 2}. Figure 1 displays RE{n(m), m} for all {n(m), m} ∈ S {n(m),m} and for the selected (n * , m * ) by the proposed approach. The efficiency gain of the selected pair compared with the reference pair {n(2), 2} ranges from 2 to 78% for varying ρ and VE 1 . Under fixed within-animal dependence, with the increase in vaccine efficacy, the maximum efficiency was achieved at a larger number of challenges and thus a smaller sample size. Under fixed vaccine efficacy, with an increase in within-animal dependence, the maximum efficiency was achieved at a larger sample size and thus a smaller number of challenges. Comparisons of the estimated RE{n(m), m} based on the two-stage method and those obtained from the standard Monte-Carlo simulations for VE 1 = 0.5 and ρ = 0.35 or 0.55 are given in supplementary material available at Biostatistics online, Figure S2 . The pattern of estimated RE{n(m), m} versus m was similar between the two.
DATA ANALYSIS
In the NHP study described by Qureshi and others (2012) , 43 adult male Rhesus Macaca mulatta (RM) were randomized to five treatment groups: Ad5 Vx-SIV (n = 9), Ad5 Vx-empty (8), Vx-SIV (9), Vxempty (9), and naive control (8). followed by 10 4 TCID 50 of virus 10 times weekly (the middle level dose), and finally 10 5 TCID 50 of virus twice a day (the highest level dose). Animals were evaluated for infection status after each challenge. Time to infection was defined as the first week in which log 10 vRNA copies are >2 and stay >2 for subsequent measurements within 4 weeks. The process of immunization can be found in detail in Qureshi and others (2012) .
Previously, Qureshi and others (2012) fit the discrete-time survival model to the data assuming homogeneous and constant risk of infection. In this section, we reanalyze the data allowing for possible heterogeneity in the risk of infection across animals and allowing for adjustment of changing dose levels over time. Results for the average risk of infection across different time periods, as presented in Qureshi and others (2012) , suggest possible differences in vaccine efficacy across challenge dose levels, particularly between the highest and the other two dose levels. To allow for some flexibility in modeling VE as a function of the challenging dose, we include the interaction term between the highest dose level and treatment assignment in the model of infection risk, in addition to main effects for each dose level and treatment:
. A similar interaction model was considered in analyzing an HIV vaccine trial in Robb and others (2012) . We fit both the homogeneous and the heterogeneous infection risk models. A goodness-of-fit test (Pan and Lin, 2005) for the proposed heterogeneous model did not show any significant deviation from the model assumptions (supplementary material available at Biostatistics online, Figure S3 in Section S6).
Using the heterogeneous model, the LRT did not find any significant within-animal dependence. However, the power to detect small heterogeneity in this study with 43 animals is very limited. Regoes (2012) studied heterogeneous susceptibility in eight datasets for HIV using an RLD design and failed to find a statistically significant heterogeneous susceptibility except for the data from Letvin 11 stm which had the largest sample size (43 animals for each of two vaccine groups). The results in Regoes (2012) and those in our analysis suggest that larger sample size is important for detecting heterogeneity in the risk of infection. Given the limited power of the test in practice, fitting a heterogeneous model to the data allowing for potential heterogeneity across animals can be useful to complement and/or confirm the results of the simpler homogeneous model, even in the presence of nonsignificant testing results.
There were no statistically significant differences identified in the risk of infection among the five vaccine groups based on the LRT ( p-value = 0.202 and 0.202 for the homogeneous and the heterogeneous models, respectively). Based on both the homogenous and heterogeneous models, estimated perchallenge VE comparing composite groups of particular interest as defined in Qureshi and others (2012) are reported along with 95% confidence intervals ( Table 4 ). The negative perchallenge vaccine efficacy estimate for Ad5-Vx-SIV vaccine against Ad5-Vx-empty or other SIV-negative vaccines in the lowest and the middle dose levels suggests a possibly greater risk of infection in the Ad5 seropositive animals immunized with the Ad5 SIV. This result is consistent with Qureshi and others (2012) . More investigation through larger studies, however, is required to confirm this observation. Estimated perchallenge probabilities of infection are given in supplementary material available at Biostatistics online, Tables S12-S14 in Section S6. Estimation of perchallenge infection risk and vaccine efficacy for each specific dose level was not achievable in earlier analyses that assumed constant infection probability and VE across challenges and animals. These measures provide valuable information to biologists for planning future RLD experiments.
DISCUSSION
In this article, we propose to fit a discrete-time survival model with random effects to take into account the potential heterogeneity among animals and the resulting within-animal dependence arising in RLD experiments. Simulation studies demonstrate that in the presence of heterogeneity, the homogeneous model ignoring within-animal dependence can have an inflated Type I error rate, loss of power for testing the vaccine's effect, biased estimates of vaccine efficacy, and low coverage rates. These problems were resolved by fitting a heterogeneous infection risk model. In the absence of between-animal heterogeneity, the heterogeneous infection risk model produces results comparable with the homogeneous infection risk model. We also propose a two-stage approach to determine the optimal balance between the number of animals and the number of challenges, in order to maximize the efficiency of VE estimates under limited resources. The usefulness of the method in designing an RLD experiment is demonstrated through simulation studies.
The heterogeneous infection risk model is more plausible from a biological point of view compared to a homogeneous model. In practice, however, most NHP studies on HIV vaccines have a small sample size with weak vaccine efficacy, which can lead to insufficient power to detect heterogeneity, as discussed in Regoes (2012) . Nevertheless, heterogeneity among animals is commonly believed to exist. Our methods address the need to assess and accommodate the existence of heterogeneity in risk modeling, even when the study may not be powerful enough to lead to significant test results. Akaike information criterion with a correction for finite sample sizes (AIC C ) of the homogeneous and the heterogeneous infection risk models including the main effects for the five vaccine groups and dose levels and their interactions for the highest dose levels are 212.12 and 216.03, respectively. AIC C = 2k − 2ˆ + 2k(k + 1)/(n − k − 1), where k is the number of parameters, n is the number of animals, andˆ is the estimated log likelihood. Smaller value is more preferred.
The heterogeneous infection risk model developed in this article is computationally advantageous. It leads to a simple closed form for the marginal likelihood function. This allows us to avoid numerical integrations that are oftentimes required for other types of random effects models. Moreover, we are able to derive vaccine efficacy as a simple function of regression parameters.
Further research in the statistical methods is warranted to accommodate more complex but realistic scenarios arising in RLD experiments. One of the worthwhile avenues of research is to relax the assumption of no "memory" of challenge history (Regoes and others, 2005; Regoes, 2012) . As challenges proceed, the differences in vaccine efficacy between vaccinated and unvaccinated groups will be diminished if previous challenges can cause immunization. Time-varying markers reflecting the potential immunization status of each animal might help investigating this issue. Identifying and modeling unintended immunization resulting from past challenges is a difficult task that requires future development in both scientific understanding and statistical techniques.
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